Software Glitch Triggers Class I Recall of Hospira Symbiq Infusion Pumps
Hospira is voluntarily recalling an infusion pump due to reports the device’s touch screen control panel may become unresponsive, according to a recent FDA bulletin.
The nationwide Class I recall, announced Oct. 29, involves one- and two-channel versions of the Hospira Symbiq Infusion System from all distribution dates.
Lake Forest, Ill.-based Hospira first informed customers of the recall in an Aug. 29 letter. While not requesting that the units be returned at the time, the letter advised operators to consult the instruction manual and double-check the dosage on the touchscreen before beginning therapy.
Simple manufacturing mishaps can lead to recalls costing devicemakers thousands of dollars. Regulatory agencies around the world could change what manufactures must do when a recall is performed, but FDAnews’ Devices & Diagnostics Letterwill keep you informed on any change or guidance these agencies might offer.
For more than 35 years, Device & Diagnostics Letter has been a must-read for leaders in the device and diagnostics industries needing to stay in compliance and avoid costly design and production mistakes. Subscribe today!
Come for this valuable opportunity to hear FDA officials discuss regulatory plans and objectives — and ask questions you need answered; learn from device industry experts, consultants and other experts with actionable tips and strategies you can take straight back to the office; and network with other professionals who understand your challenges; share war stories and insights over a drink. Register Today.Read More
The FDA's new enforcement plan makes one thing clear: Developing a successful CAPA program has never been more important. But creating an FDA-proof CAPA isn’t easy. If only you could pick the brain of someone who is coping successfully with CAPA — the best and the brightest, an industry leader who has devised programs, procedures and solutions that have put companies out in front with the FDA. Well, you can. Register today.Read More
The FDA’s cadre of freshly trained inspectors — many of whom come directly from industry — and increased focus on specialized inspections are making it harder than ever to predict the outcome of your next FDA inspection. Unless, of course, you have Surviving an FDA Inspection at your fingertips. If you could spend less than $400 to get your drug manufacturing facility fully prepared to face a tough inspection by the FDA, would you even hesitate? ... Of course not!